Presented by Dr Lisa Salvatore (Fondazione Policlinico Universitario Agostino Gemelli, IRCCS – Rome, Italy)
A recent analysis of the CodeBreaK 300 study has been conducted to investigate potential mechanisms of resistance to the combination of sotorasib and panitumumab in patients with advanced cancers. The focus was on patients who had liquid biopsy samples available at both baseline and disease progression, which included a relatively small cohort of 30 patients per treatment arm. At the ASCO 2025 poster session, Dr Lisa Salvatore presented a poster on this topic.
The main findings showed that the overall number of newly emergent alterations at the time of disease progression, as well as the patterns and distribution of these alterations, did not differ significantly between the treatment arms. This suggests a similar landscape of acquired resistance mechanisms regardless of the treatment approach.
However, a notable observation was that patients treated with the combination of sotorasib and panitumumab exhibited a higher number of newly emergent KRAS alterations beyond the original KRAS G12C mutation, as well as an increased incidence of copy number gains.
The emergence of additional KRAS alterations and increased copy number gains could contribute to resistance to sotorasib plus panitumumab, underscoring the need for further investigation. Understanding these resistance pathways will be critical for the development of next-generation therapies and for identifying strategies to overcome resistance in this challenging patient population.
References:
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in